checkAd
    Startseite > Aktien > Adverum Biotechnologies > Nachrichten
    Adverum Biotechnologies Aktie
    7,9200
     
    USD
    +1,41 %
    +0,1100 USD
    Letzter Kurs 02:00:00 Nasdaq
    7,9200
     
    USD
    500 STK
    Geldkurs 31.05.24
    7,9600
     
    USD
    100 STK
    Briefkurs 31.05.24
    ISIN: US00773U2078 · WKN: A404YL · SYM: ADVM · USA

    Neueste Nachrichten

    Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
    18.03.24 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
    28.02.24 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    12.02.24 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
    08.02.24 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
    05.02.24 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
    01.02.24 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
    29.01.24 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
    28.11.23 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
    09.11.23 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
    06.11.23 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
    04.11.23 · globenewswire · Adverum Biotechnologies
    Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
    26.09.23 · globenewswire · Adverum Biotechnologies